Ignite Creation Date:
2024-05-06 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04707950
Status:
UNKNOWN
Last Update Posted:
2021-01-13
First Post:
2020-02-25
Brief Title:
Tranexamic Acid for the Prevention of Postpartum Haemorrhage
Sponsor:
Benha University
Organization:
Benha University
Study Overview
Official Title:
Use of Tranexamic Acid for the Prevention of Postpartum Haemorrhage After Cesarean Section in High-risk Patients a Randomized Control Trial
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Use of tranexamic acid TXA for the prevention of postpartum haemorrhage PPH after cesarean section in high-risk patients a randomized control trial
Detailed Description:
Participants will be divided into two groups a study group a control group In addition to the standard management the study group will be given TXA 1 gm 100 mgml slowly intravenous infusion during delivery after clamping of the cord administered over 10 minutes at 1 mlminute
The second dose of TXA 1 g Intravenous can be given if
Bleeding continues after 30 minutes
Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups amount of blood loss during operation to assess efficacy of TXA in prevention of PPH and reduction of intra and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements
The second dose of TXA 1 g Intravenous can be given if
Bleeding continues after 30 minutes
Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups amount of blood loss during operation to assess efficacy of TXA in prevention of PPH and reduction of intra and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None